Array BioPharma Owners | StatInvestor

Health Care & Life Sciences » Biotechnology | Array BioPharma Inc.

Array BioPharma Inc. | Ownership

Companies that own Array BioPharma Inc.

Name

Shares Held

% Shares Out

Change In Shares

% of Assets

As of Date

Fidelity Management & Research Co.

24,390,396

11.48%

787,460

0.04%

06/30/2018

The Vanguard Group, Inc.

22,652,811

10.66%

1,106,673

0.01%

06/30/2018

Redmile Group LLC

15,978,580

7.52%

-1,245,848

7.7%

06/30/2018

BlackRock Fund Advisors

15,186,821

7.15%

846,534

0.01%

06/30/2018

Franklin Advisers, Inc.

8,257,626

3.89%

74,359

0.09%

06/30/2018

SSgA Funds Management, Inc.

7,681,261

3.61%

-293,433

0.01%

06/30/2018

T. Rowe Price Associates, Inc.

6,621,180

3.12%

573,664

0.01%

06/30/2018

Baker Bros. Advisors LP

5,656,196

2.66%

0.56%

06/30/2018

OrbiMed Advisors LLC

4,900,900

2.31%

0.8%

06/30/2018

BVF Partners LP

4,672,195

2.2%

-390,573

4.9%

06/30/2018

About Array BioPharma

View Profile

Address	3200 Walnut Street Boulder Colorado 80301 United States
Employees	-
Website	http://www.arraybiopharma.com
Updated	07/08/2019
Array BioPharma, Inc. engages in the research, development, and commercialization of targeted small molecule drugs for the treatment of cancer and other high-burden diseases. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony Piscopio, K.